Tenofovir to stop liver disease in mild hepatitis B
Part of Digestive system, Infections clinical trials.
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hepatitis B infection confirmed by a positive HBsAg blood test
- Your liver blood tests (ALT) stay normal on repeat checks 3–6 months apart
- Your hepatitis B virus level (HBV DNA) is low, under 2000 IU/ml
- Your liver stiffness test (LSM) is below 8 kPa
- You have never taken hepatitis B medicines from the nucleos(t)ide/nucleotide or interferon (IFN) group before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
This trial tests whether switching to a newer antiviral medicine called tenofovir alafenamide (TAF, a pill for hepatitis B) is safe and works well for people who have had a liver transplant. The goal is to keep the liver healthy and reduce side effects compared to current treatment.
This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.
This study compares two approved hepatitis B medicines—tenofovir alafenamide and entecavir—to see which works best for people with chronic hepatitis B. It may help improve control of the virus and support better long-term liver health.
This trial tests whether a newer hepatitis B drug (tenofovir alafenamide) works as well and is as safe as the older drug (tenofovir disoproxil fumarate) for preventing hepatitis B from becoming active in people with blood cancers who are getting treatments that weaken the immune system.
This trial studies what happens after stopping long-term hepatitis B antiviral medicine in people whose virus has stayed controlled. It also follows patients over time to see how well they remain stable and safe after stopping.
Hear when a new Non-cirrhotic, Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.